ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza. The company has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting Gram-negative bacteria; and license agreement with Trellis Bioscience LLC for mAbs in the field of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone914-207-2300
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees20
Next Earnings Date5/9/2019 (Estimated)
OptionableNot Optionable
ContraFect (NASDAQ:CFRX) Frequently Asked Questions
What is ContraFect's stock symbol?
ContraFect trades on the NASDAQ under the ticker symbol "CFRX."
How were ContraFect's earnings last quarter?
ContraFect Corp (NASDAQ:CFRX) issued its earnings results on Thursday, March, 14th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.17. View ContraFect's Earnings History.
When is ContraFect's next earnings date?
What price target have analysts set for CFRX?
3 equities research analysts have issued 1 year price objectives for ContraFect's stock. Their forecasts range from $2.80 to $2.80. On average, they expect ContraFect's stock price to reach $2.80 in the next year. This suggests a possible upside of 419.4% from the stock's current price. View Analyst Price Targets for ContraFect.
What is the consensus analysts' recommendation for ContraFect?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ContraFect in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ContraFect.
Has ContraFect been receiving favorable news coverage?
Media coverage about CFRX stock has trended positive this week, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. ContraFect earned a daily sentiment score of 2.4 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are some of ContraFect's key competitors?
Some companies that are related to ContraFect include Adamas Pharmaceuticals (ADMS), Zynerba Pharmaceuticals (ZYNE), BELLUS Health (BLUSF), REDHILL BIOPHAR/S (RDHL), Menlo Therapeutics (MNLO), AgeX Therapeutics (AGE), Tyme Technologies (TYME), Newron Pharmaceuticals (NWPHF), Axovant Sciences (AXGT), Verastem (VSTM), Galmed Pharmaceuticals (GLMD), Syndax Pharmaceuticals (SNDX), Aquestive Therapeutics (AQST), LifeVantage (LFVN) and Humanigen (HGEN).
What other stocks do shareholders of ContraFect own?
Who are ContraFect's key executives?
ContraFect's management team includes the folowing people:
- Dr. Steven C. Gilman, Exec. Chairman, CEO & Pres (Age 66)
- Mr. Michael Messinger CPA, CPA, CFO & Chief Accounting Officer (Age 44)
- Ms. Nancy Dong, VP of Fin. & Admin. (Age 54)
- Ms. Natalie Bogdanos J.D., Gen. Counsel, Corp. Sec. & Data Protection Officer (Age 50)
- Dr. Cara Cassino, Chief Medical Officer and Exec. VP of R&D (Age 57)
Who are ContraFect's major shareholders?
ContraFect's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Hartwell J M Limited Partnership (0.13%). Company insiders that own ContraFect stock include Cara M Cassino, Fosun Pharmaceutical Shanghai, Joshua B Muntner, Sol J Barer and Steven C Gilman. View Institutional Ownership Trends for ContraFect.
Which institutional investors are buying ContraFect stock?
CFRX stock was acquired by a variety of institutional investors in the last quarter, including Hartwell J M Limited Partnership. Company insiders that have bought ContraFect stock in the last two years include Cara M Cassino, Joshua B Muntner, Sol J Barer and Steven C Gilman. View Insider Buying and Selling for ContraFect.
How do I buy shares of ContraFect?
Shares of CFRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ContraFect's stock price today?
One share of CFRX stock can currently be purchased for approximately $0.5391.
How big of a company is ContraFect?
ContraFect has a market capitalization of $42.81 million. The biotechnology company earns $-37,680,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. ContraFect employs 20 workers across the globe.
What is ContraFect's official website?
How can I contact ContraFect?
ContraFect's mailing address is 28 WELLS AVENUE 3RD FLOOR, YONKERS NY, 10701. The biotechnology company can be reached via phone at 914-207-2300 or via email at [email protected]
MarketBeat Community Rating for ContraFect (NASDAQ CFRX)
MarketBeat's community ratings are surveys of what our community members think about ContraFect and other stocks. Vote "Outperform" if you believe CFRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CFRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
